Lurasidone for the treatment of irritability and anger in autism spectrum disorders

References

• Amercian Psychiatric Association. Diagnostic and statistical manual of mental disorders: DSM-5. Washington, D.C; American Psychiatric Association 2013.
   Google Scholar
• McDougle, C.J., et al. Research Units on Pediatric Psychopharmacology (RUPP) Autism network. Background and rationale for an initial controlled study of risperidone. Child Adolesc Psychiatr Clin N Am. 2000;9:201–224.
   PubMed Web of Science ®Google Scholar
• Fitzpatrick S, Srivorakiat L, Wink LK, et al. Aggression in autism spectrum disorder: presentation and treatment options. Neuropsychiatr Dis Treat. 2016;12:1525–1538.
   PubMed Web of Science ®Google Scholar
• Nakako T, Murai T, Ikejiri M, et al. Effects of lurasidone on ketamine-induced joint visual attention dysfunction as a possible disease model of autism spectrum disorders in common marmosets. Behav Brain Res. 2014;274:349–354.
   PubMed Web of Science ®Google Scholar
• Cooper JO, Heron TE, Heward WL. Applied behavior analysis. Columbus: Merrill Pub. Co; 1987.
   Google Scholar
• DeFilippis M, Wagner K. Treatment of Autism spectrum disorder in children and adolescents. Psychopharmacy Bull. 2016;46:18–41.
   PubMedGoogle Scholar
• McCracken JT, McGough J, Shah B, et al. Risperidone in children with autism and serious behavioral problems. N Engl J Med. 2002;347:314–321.
   PubMed Web of Science ®Google Scholar
• Shea, S., et al. Risperidone in the treatment of disruptive behavioral symptoms in children with autistic and other pervasive developmental disorders. Pediatrics. 2004;114:634–641.
   PubMed Web of Science ®Google Scholar
• Owen R, Sikich L, Marcus RN, et al. Aripiprazole in the treatment of irritability in children and adolescents with autistic disorder. Pediatrics. 2009;124:1533–1540.
   PubMed Web of Science ®Google Scholar
• Findling R, et al.. Pharmacokinetic and safety evaluation of lurasidone in pediatric patients with psychiatric disorders. European Psychiatry. 2015;30:1202.
   Web of Science ®Google Scholar
• Council NAMH, From discovery to cure: accelerating the development of new and personalized interventions for mental illnesses. NIMH;2010
   Google Scholar
• O’Brien PL, Thomas CP, Hodgkin D, et al. The diminished pipeline for medications to treat mental health and substance use disorders. Psychiatr Serv. 2014;65:1433–1438.
   PubMed Web of Science ®Google Scholar
• Bruijnzeel D, Yazdanpanah M, Suryadevara U, et al. Lurasidone in the treatment of schizophrenia: a critical evaluation. Expert Opin Pharmacother. 2015;16:1559–1565.
   PubMed Web of Science ®Google Scholar
• Mauri MC, Paletta S, Maffini M, et al. Clinical pharmacology of atypical antipsychotics: an update. Excli J. 2014;13:1163–1191.
   PubMed Web of Science ®Google Scholar
• Erickson CA, Stigler KA, Posey DJ, et al. Aripiprazole in autism spectrum disorders and fragile X syndrome. Neurotherapeutics. 2010;7:258–263.
   PubMed Web of Science ®Google Scholar
• DeLeon A, Patel NC, Crismon ML. Aripiprazole: a comprehensive review of its pharmacology, clinical efficacy, and tolerability. Clin Ther. 2004;5:649–666.
   Web of Science ®Google Scholar
• Jaeschke RR, Sowa-Kućma M, Pańczyszyn-Trzewik P, et al. Lurasidone: the 2016 update on the pharmacology, efficacy and safety profile. Pharmacol Rep. 2016;68:748–755.
   PubMed Web of Science ®Google Scholar
• Preskorn S, Ereshefsky L, Chiu -Y-Y, et al. Effect of food on the pharmacokinetics of lurasidone: results of two randomized, open-label, crossover studies. Hum Psychopharmacol. 2013;28:495–505.
   PubMed Web of Science ®Google Scholar
• Nakamura M, Ogasa M, Guarino J, et al. Lurasidone in the treatment of acute schizophrenia: a double-blind, placebo-controlled trial. J Clin Psychiatry. 2009;70:829–836.
   PubMed Web of Science ®Google Scholar
• Meltzer HY, Cucchiaro J, Silva R, et al. Lurasidone in the treatment of schizophrenia: a randomized, double-blind, placebo- and olanzapine-controlled study. Am J Psychiatry. 2011;168:957–967.
   PubMed Web of Science ®Google Scholar
• Loebel A, Cucchiaro J, Sarma K, et al. Efficacy and safety of lurasidone 80 mg/day and 160 mg/day in the treatment of schizophrenia: a randomized, double-blind, placebo- and active-controlled trial. Schizophr Res. 2013;145:101–109.
   PubMed Web of Science ®Google Scholar
• Nasrallah HA, Silva R, Phillips D, et al. Lurasidone for the treatment of acutely psychotic patients with schizophrenia: a 6-week, randomized, placebo-controlled study. J Psychiatr Res. 2013;47:670–677.
   PubMed Web of Science ®Google Scholar
• Loebel, A., et al. Lurasidone as adjunctive therapy with lithium or valproate for the treatment of bipolar I depression: a randomized, double-blind, placebo-controlled study. Am J Psychiatry. 2014;171:169–177.
   PubMed Web of Science ®Google Scholar
• Loebel A, Cucchiaro J, Silva R, et al. Lurasidone monotherapy in the treatment of bipolar I depression: a randomized, double-blind, placebo-controlled study. Am J Psychiatry. 2014;171:160–168.
   PubMed Web of Science ®Google Scholar
• Ogasa M, Kimura T, Nakamura M, et al. Lurasidone in the treatment of schizophrenia: a 6-week, placebo-controlled study. Psychopharmacology (Berl). 2013;225:519–530.
   PubMed Web of Science ®Google Scholar
• Millard PH, McClaren JL, Coffey B. Lurasidone treatment in a child with autism spectrum disorder with irritability and aggression. Advan Pediatric Psychopharm. 2014;24:354–356.
   Google Scholar
• Loebel A, Brams M, Goldman RS, et al. Lurasidone for the treatment of irritability associated with autistic disorder. J Autism Dev Disord. 2016;46:1153–1163.
   PubMed Web of Science ®Google Scholar
• American Psychiatric Association. Diagnostic and statistical manual of mental disorders, 4thedn, text rev. Washington, DC; American Psychiatric Association, 2000.
   Google Scholar
• Aman MG, Singh NN, Stewart AW, et al. The aberrant behavior checklist: a behavior rating scale for the assessment of treatment effects. Am J Ment Defic. 1985;89:485–491.
   PubMedGoogle Scholar
• Guy W. Clinical global impression (CGI). Rockville: U.D.o.H. Editor; 1976.
   Google Scholar
• Scahill L, McDougle CJ, Williams SK, et al. Children’s yale-brown obsessive compulsive scale modified for pervasive developmental disorders. J Am Acad Child Adolesc Psychiatry. 2006;45:1114–1123.
   PubMed Web of Science ®Google Scholar
• Brannan AM, Bickman L. The caregiver strain questionnaire: measuring the impact on the family of living with a child with serious emotional disturbance. J Emot Behav Disord. 1997;5:212–222.
   Web of Science ®Google Scholar
• Simpson GM, Angus JWS. A rating scale for extrapyramidal side effects. Acta Psychiatr. 1970;Supp 212:11–19.
   Google Scholar
• National Institute of Mental Health, (NIMH). Abnormal involuntary movement scale (AIMS). Early Clin Drug Eval Unit Intercom. 1975;4:3–6.
   Google Scholar
• Barnes TRE. A rating scale for drug-induced akathisia. Br J Psychiatry. 1989;154:672–676.
   PubMed Web of Science ®Google Scholar
• Millard PH, McLaren JL, Coffey DB. Lurasidone treatment in a child with autism spectrum disorder with irritability and aggression. J Adolesc Psychopharmacol. 2014;24:354–356.
   PubMed Web of Science ®Google Scholar
• Devlin AM, Panagiotopoulos C. Metabolic side effects and pharmacogenetics of second-generation antipsychotics in children. Pharmacogenomics. 2015;16:981–996.
   PubMed Web of Science ®Google Scholar
• Marcus RN, Owen R, Manos G, et al. Safety and tolerability of aripiprazole for irritability in pediatric patients with autistic disorder: a 52-week, open-label, multicenter study. J Clin Psychiatry. 2011;72:1270–1276.
   PubMed Web of Science ®Google Scholar
• Ronsley R, Nguyen D, Davidson J, et al. Increased risk of obesity and metabolic dysregulation following 12 months of second-generation antipsychotic treatment in children: a prospective cohort study. Can J Psychiatry. 2015;60:441–450.
   PubMed Web of Science ®Google Scholar
• Shedlock K, Susi A, Gorman GH, et al. Autism spectrum disorders and metabolic complications of obesity. J Pediatr. 2016;178:183–7.e1.
   PubMed Web of Science ®Google Scholar
• Politte LC, McDougle CJ. Atypical antipsychotics in the treatment of children and adolescents with pervasive developmental disorders. Psychopharmacology. 2014;231:1023–1036.
   PubMed Web of Science ®Google Scholar
• Wink, L.K., et al. Emerging drugs for the treatment of symptoms associated with autism spectrum disorders. Expert Opin Emerg Drugs. 2010;15:481–494.
   PubMed Web of Science ®Google Scholar
• Erickson, C.A., et al. An open-label naturalistic pilot study of acamprosate in youth with autistic disorder. J Child Adolesc Psychopharmacol. 2011;21:565–569.
   PubMed Web of Science ®Google Scholar
• Wink, L.K., et al. Riluzole in autistic disorder. J Child Adolesc Psychopharmacol. 2011;21:375–379.
   PubMed Web of Science ®Google Scholar
• Erickson, C.A., et al. Impact of acamprosate on behavior and brain-derived neurotrophic factor: an open-label study in youth with fragile X syndrome. Psychopharmacology (Berl). 2013;228:75–84.
   PubMed Web of Science ®Google Scholar
• Erickson, C.A., et al. STX209 (arbaclofen) for autism spectrum disorders: an 8-week open-label study. J Autism Dev Disord. 2014;44:958–964.
   PubMed Web of Science ®Google Scholar
• Erickson, C.A., et al. Impact of acamprosate on plasma amyloid-β precursor protein in youth: a pilot analysis in fragile X syndrome-associated and idiopathic autism spectrum disorder suggests a pharmacodynamic protein marker. J Psychiatr Res. 2014;59:220–228.
   PubMed Web of Science ®Google Scholar
• Schaefer TL, Davenport MH, Erickson CA. Emerging pharmacologic treatment options for fragile X syndrome. Appl Clin Genet. 2015;8:75–93.
   PubMedGoogle Scholar
• Wink, L.K., et al. A randomized placebo-controlled pilot study of N-acetylcysteine in youth with autism spectrum disorder. Mol Autism. 2016;7:26.
   PubMed Web of Science ®Google Scholar
• Ciranna L, Catania MV. 5-HT7 receptors as modulators of neuronal excitability, synaptic transmission and plasticity: physiological role and possible implications in autism spectrum disorders. Front Cell Neurosci. 2014;8.
   PubMed Web of Science ®Google Scholar
• Owley T, Brune CW, Salt J, et al. A pharmacogenetic study of escitalopram in autism spectrum disorders. Autism Res. 2010;3:1–7.
   PubMed Web of Science ®Google Scholar
• Takahashi, A., et al. Behavioral and pharmacogenetics of aggressive behavior. Curr Behav Sci. 2012;12:73–138.
   Google Scholar
• Pouget, J.G., et al. Pharmacogenetics in schizophrenia. Dialogues Clin Neurosci. 2014;16:555–566.
   PubMed Web of Science ®Google Scholar
• Brandl EJ, Kennedy JL, Muller DJ. Pharmacogenetics of antipsychotics. Can J Psychiatry. 2014;59:76–88.
   PubMed Web of Science ®Google Scholar
• Bowers K, Lin PI, Erickson C. Pharmacogenomic medicine in autism: challenges and opportunities. Paediatr Drugs. 2015;17:115–124.
   PubMed Web of Science ®Google Scholar
• Sukasem C, Hongkaew Y, Ngamsamut N, et al. Impact of pharmacogenetic markers of CYP2D6 and DRD2 on prolactin response in risperidone-treated thai children and adolescents with autism spectrum disorders. J Clin Psychopharmacol. 2016;36:141–146.
   PubMed Web of Science ®Google Scholar
• Lee YJ, Oh SH, Park C, et al. Advanced pharmacotherapy evidenced by pathogenesis of autism spectrum disorder. Clin Psychopharmacol Neurosci. 2014;12:19–30.
   PubMed Web of Science ®Google Scholar
• Youngster I, Zachor DA, Gabis LV, et al. CYP2D6 genotyping in paediatric patients with autism treated with risperidone: a preliminary cohort study. Dev Med Child Neurol. 2014;56:990–994.
   PubMed Web of Science ®Google Scholar
• Najjar F, Owley T, Mosconi MW, et al. Pharmacogenetic study of serotonin transporter and 5HT2A genotypes in Autism. J Child Adolesc Psychopharmacol. 2015;25:467–474.
   PubMed Web of Science ®Google Scholar
• Puangpetch A, Vanwong N, Nuntamool N, et al. CYP2D6 polymorphisms and their influence on risperidone treatment. Pharmgenomics Pers Med. 2016;9:131–147.
   PubMed Web of Science ®Google Scholar
• Autismspeaks Inc., A. Why is autism associated with aggressive and challenging behaviors? 2012.
   Google Scholar